Systemic sclerosis is associated with knee arthroplasty outcomes: a National US study
- 81 Downloads
To assess whether systemic sclerosis (SSc) is associated with total knee arthroplasty (TKA) outcomes.
We used the 1998–2014 US National Inpatient Sample. We conducted multivariable-adjusted logistic regression analyses to examine the association of a diagnosis of SSc with post-TKA in-hospital complications (implant infection, revision, transfusion, mortality) and healthcare utilization (hospital charges, hospital stay, non-home vs. home discharge). Odds ratios (OR) and 95 % confidence intervals (CI) were calculated.
Our cohort included 8,123,388 people without SSc and 3894 people with SSc. In multivariable-adjusted analyses, compared to people without SSc, people with SSc had higher odds of transfusion, hospital stay > 3 days and non-home discharge with higher OR of 1.42 (95 % CI, 1.20, 1.69), 1.29 (95 % CI, 1.11, 1.49), and 1.29 (95 % CI, 1.11, 1.49), respectively. No differences were seen in revision, 0.68 (95 % CI, 0.10, 4.69) or hospital charges above the median, 1.01 (95 % CI, 0.70, 1.46). Differences in implant infection or mortality were not estimable, since none of the patients with SSc had implant infection or died. Sensitivity analyses that adjusted the main analysis additionally for hospital-level variables confirmed study findings with minimal or no attenuation of OR.
• Systemic sclerosis was independently associated with higher healthcare utilization after TKA.
• The adjusted odds of transfusion was higher in people with systemic sclerosis compared to those without systemic sclerosis who underwent TKA.
KeywordsSystemic sclerosis Total knee arthroplasty National Inpatient Sample Healthcare utilization TKA In-hospital complications Outcomes
JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.
Compliance with ethical standards
Conflict of interest
There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. JDC has no conflicts.
The study was approved by the Institutional Review Board (IRB) at the University of Alabama at Birmingham (UAB; X120207004).
- 1.Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA Jr, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD (2014) Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) 66:489–495CrossRefGoogle Scholar
- 4.Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M, Noel LH, Trolliet P, Frances C, Cabane J, Guillevin L, for the Group Francais de Recherche sur le Sclerodermie (GFRS) (2008) Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67:110–116CrossRefGoogle Scholar
- 12.Singh JA, Yu S, Chen L, Cleveland JD (2019) Rates of total joint replacement in the United States: future projections to 2020-2040 using the National Inpatient Sample. J Rheumatol:jrheum.170990Google Scholar
- 13.HCUP Databases. Healthcare Cost and Utilization Project (HCUP). Overview of the Nationwide Inpatient Sample (NIS). http://www.hcup-us.ahrq.gov/nisoverview.jsp. Last modified 8/13/18. In. Rockville, MD: Agency for Healthcare Research and Quality; 2018
- 14.HCUP. Overview of the National (Nationwide) Inpatient Sample (NIS). https://www.hcup-us.ahrq.gov/nisoverview.jsp. In. Rockville, MD: AHRQ; 2018
- 17.Whalen D, Houchens R, Elixhauser A. Final 2000 NIS comparison report. HCUP methods series report#2003–1. Available at: http://www.hcup-us.ahrq.gov/reports/2000NISComparisonReportFinal.pdf. In. Rockville, MD: AHRQ; 2003
- 18.Agency for Healthcare Research and Quality. HCUP quality control procedures. www.ahrq.gov/data/hcup/sasddocu/techsupp2.pdf. In. Rockville, MD: Agency for Healthcare Research and Quality; 2002
- 19.Malcolm TL, Knezevic NN, Zouki CC, Tharian AR (2019) Pulmonary complications after hip and knee arthroplasty in the United States, 2004-2014. Anesth Analg:1Google Scholar
- 36.Medicare Eligibility: Who may enroll in Medicare. https://www.ehealthmedicare.com/about-medicare/eligibility/. In. Baltimore, MD: Centers for Medicare and Medicaid Services; 2017
- 37.Kretzschmar M, Heilmeier U, Yu A, Joseph GB, Liu F, Solka M, McCulloch CE, Nevitt MC, Link TM (2016) Longitudinal analysis of cartilage T2 relaxation times and joint degeneration in African American and Caucasian American women over an observation period of 6 years - data from the Osteoarthritis Initiative. Osteoarthr Cartil 24:1384–1391CrossRefGoogle Scholar
- 38.HCUP NIS Description of Data Elements. Healthcare Cost and Utilization Project (HCUP). September 2008. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nisnote.jsp. In. Bethesda, MD: Agency for Health Care Research and Quality; 2017